Table 2 Epidemiological and clinical characteristics of patients in relation to EBV DNA
From: Serum EBV antibodies and LMP-1 in Polish patients with oropharyngeal and laryngeal cancer
EBV DNA+ | EBV DNA- | p | ||||
|---|---|---|---|---|---|---|
n | % | n | % | |||
Sex | female | 0 | 0 | 8 | 100 | 0.0282* |
male | 58 | 56.9 | 44 | 43.1 | ||
Age | <49 | 8 | 50.0 | 4 | 50.0 | 0.8969 |
50–59 | 22 | 47.8 | 24 | 52.2 | ||
>60 | 28 | 50.0 | 24 | 50.0 | ||
Place of residence | urban | 40 | 55.6 | 32 | 44.4 | 0.5630 |
rural | 18 | 47.4 | 20 | 52.6 | ||
Smoking | yes | 50 | 53.2 | 44 | 46.8 | 0.8672 |
no | 8 | 50.0 | 8 | 50.0 | ||
Alcohol abuse | yes | 28 | 56.0 | 22 | 44.0 | 0.6571 |
no | 30 | 50.0 | 30 | 50.0 | ||
Histological grading | G1 | 22 | 61.1 | 14 | 38.9 | 0.6852 |
G2 | 34 | 48.57 | 36 | 51.43 | ||
G3 | 2 | 50.0 | 2 | 50.0 | ||
T stage | T1 | 6 | 42.9 | 8 | 57.1 | 0.1826 |
T2 | 28 | 58.3 | 20 | 41.7 | ||
T3 | 16 | 72.7 | 6 | 27.3 | ||
T4 | 8 | 30.8 | 18 | 69.2 | ||
N stage | N0 | 30 | 51.7 | 28 | 48.3 | 0.9768 |
N1 | 10 | 50.0 | 10 | 50.0 | ||
N2 | 14 | 58.3 | 10 | 41.7 | ||
N3 | 4 | 50.0 | 4 | 50.0 | ||
M stage | M0 | 58 | 52.7 | 52 | 47.3 | |
M1 | 0 | 0 | 0 | 0 | ||
Location of cancer | pharynx | 23 | 50.0 | 23 | 50.0 | 0.6452 |
larynx | 35 | 54.7 | 29 | 45.3 | ||
EBV type | wild | 48 | 82.8 | - | - | - |
del-LMP1 | 10 | 17.2 | - | - | ||